Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer
|
|
- Anna Tyler
- 5 years ago
- Views:
Transcription
1 Med. J. Cairo Univ., Vol. 82, No. 2, March: , Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy in the Treatment of Locally Advanced Cervical Cancer RASHA M. ABDEL-LATIF, M.D.*; ABEER H. ANTER, M.D.* and MOHAMED A. HUSSEIN, M.D.** The Department of Clinical Oncology & Nuclear Medicine, Faculties of Medicine, Mansoura* and Al-Azhar* * Universities Abstract Objective: To compare compliance, toxicity, and outcome as regard overall survival and progression free survival of weekly taxol vs. weekly cisplatin administration concurrently with radiotherapy in locally advanced cervical cancer. Material and Methods: This prospective study included 57 women FIGO stage IB2-IVA cervical cancer or with postsurgical pelvic recurrence. Patients randomized into two groups, group I (29 patients) received a weekly cisplatin 40mg/m2 and group II (28 patients) received weekly 50mg/m 2 taxol concurrently with radiotherapy. The difference of compliance and toxicity profiles between the two arms were investigated, and the overall and progression free survival were analysed. Results: Patients and tumor characteristics were similar in both arms, except the median tumor size was larger in group II (5.5cm) but not significant (P= ). The mean number of chemotherapy cycles was comparable, with 88.4% and 84% of patients receiving 4 doses in group I and II, respectively. There was no statistically significant difference of compliance between the two arms ( p>0.05). Two years Progression free survival rate was 45% in arm I and 38% in arm II, with no statistically significant difference (p=0.8). The median overall survival in arm I was 27 months and, 26 months in arm II, with no statistically significant difference (p=0. 16). Conclusion: This small prospective study shows that weekly paclitaxel does not provide any clinical advantage over weekly cisplatin for concurrent chemoradiation for advanced carcinoma of the cervix. Key Words: Locally advanced cancer cervix Weekly cisplatin Weekly taxol Concurrent chemoradiation. Introduction CERVICAL cancer is one of the most common gynecologic cancer world wide [1]. The prognosis of cervical cancer is favorable in early stage while advanced disease carries a poor prognosis. Radia- Correspondence to: Dr. Rasha M. Abdel-Latif, The Department of Clinical Oncology & Nuclear Medicine, Faculty of Medicine, Mansoura University tion therapy remains the main treatment modality for patients with advanced cervical cancer [2,3]. Several randomized trials revealed that the treatment regimens combining radiotherapy with platinum based chemotherapy improve rates of overall survival (OAS) and progression free survival (PFS) in women with stage IIIB through IVA [4-6]. At first it was reported positive result with the use of concurrent cisplatin and 5-fluorouracil (5-FU) with radiotherapy, then gradually replaced cisplatin and 5-FU with weekly cisplatin because of less toxicity with weekly cisplatin [7]. Ryu et al., reported that triweekly cisplatin 75mg/m2 chemotherapy concurrent with radiotherapy was more effective and feasible than the conventional weekly cisplatin 40mg/m 2 [8]. However, others reported no differentiation in PFC and OAS between two groups [9]. A study by National Cancer Institute of Canada using weekly concurrent single agent cisplatin has shown no clinical benefit from this schedule [10]. This fact have stimulated interest in exploring other concurrent combination with potentially more clinical effect. The efficacy of paclitaxel has been tested in metastatic and recurrent cervical cancer with objective response rates [11]. Paclitaxel was found to have radiosensitizing effects in human cervical cancer [12,13]. The clinical feasibility of concurrent radiotherapy and paclitaxel was tested and a maximum tolerated dose of 50mg/m 2 per week concurrent with radiotherapy was established [14,15]. Fady et al., was reported that overall response and PFS rates with paclitaxel not superior to those with cisplatin for patients with advanced cervical cancer [16]. 351
2 352 Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy In our study we tried to compare between weekly cisplatin versus paclitaxel concurrent radiotherapy in patients with advanced cervical cancer as regard PFS and overall response. Material and Methods Patients presenting to Clinical Oncology and Nuclear Medicine Department, Mansoura University Hospital and Clinical Oncology Department, Al-Hussien University Hospital, with advanced carcinoma of the cervix, stages IB2-IVA according to the Federation Internationale de Gynecologie Obstetrique (FIGO) staging system, or with measurable central pelvic recurrence, were eligible to enroll in this phase II randomized prospective study. Inclusion criteria also included: Age <80 years, Gynecologic Oncology Group (GOG) performance status of 0-2, and adequate hematological and biochemical profile with absolute neutrophil count > 1.5x 1 0 9/L, platelets > 1 00x 1 0 9/L, creatinine <1.5, liver enzymes (AST and ALT) <3 x normal, and bilirubin <1.25 normal. Patients with evidence of enlarged paraaortic lymphnodes, history of peripheral neuropathy, prior radiotherapy, prior chemotherapy (neoadjuvant), hypersensitivity to cisplatin or paclitaxel, or other synchronous malignancies were excluded. Between October 2010 to July 2013, 57 women were enrolled and randomized to receive on a weekly basis either 40mg/m 2 Cisplatin (group I; 29 patients) or 50mg/m 2 paclitaxel (group II; 28 patients) concurrently with radiotherapy. Treatment: Chemotherapy: Patients were randomized into two groups: Group 1 treated with weekly cisplatin and group 2 treated with weekly paclitaxel. Group I patients received weekly cisplatin at a dose of 40mg/m 2 diluted in 250mL of 0.9% sodium chloride was administered i.v. over 1h. Premedication consisted of dexamethasone 8mg IV, and a 5HT3-receptor antagonist as antiemetic with hydration at least 500mL of 0.9% sodium chloride was injected i.v before and after cisplatin administration. Group II patients were treated with weekly paclitaxel 50mg/m 2 given intravenously in 500cc of glucose 5% in a glass container over three hours. Premedication consisted of dexamethasone 8mg IV, avil 1 ml IV, Ranitidine 50mg IV, and a 5HT3-receptor antagonist as antiemetic. Planned treatment was for an average of 5-6 cycles to coincide with the duration of external beam radiation. Radiation therapy: All patients were treated with a combination of external-beam radiotherapy (EBRT) and intracavitary brachytherapy (ICBT). External-beam radiotherapy was delivered to the whole pelvis through a four-field box technique using MV photons, The planned total dose to the whole pelvis was 45-50Gy in fraction over weeks. When patients had bulky parametrial tumors or gross lymph node metastases, an additional 5-1 0Gy was applied to boost the external dose to the lesion to a total of 55-60Gy with central shields (CS) inserted during EBRT of additional 5-10Gy to reduce organ at risk (OAR) exposure depending on tumor shrinkage. Central shields (CS) was carried about 4cm in width at the isocenter of the field. Low Dose Rate (LDR) brachytherapy was used after the completion of EBRT using two insertions with 137 Cs source. These include the placement of an intrauterine tandem with vaginal ovoids, the addition of the ovoids or ring to the tandem applicator may be used to provides a dose distribution that encompasses the at-risk paracervical tissues while providing a lower dose distribution to the bladder and rectum. In addition, dose to the bladder and rectum can be reduced further with the use of vigorous packing. The choice of applicator is governed by physician preference and comfort level, as well as patient anatomical considerations. Applicator placement typically requires intravenous conscious sedation or general anesthesia for patient comfort. Once the applicators are in place, treatments are traditionally planned using orthogonal radiographs to define prescription and normal tissue points of interest (Fig. 1). Dose to surrounding organs at risk were calculated at bladder, rectal and pelvic points. The planned dose prescribed to the point A was 30-40Gy in 1 to 2 fractions according to the tumor volume. The total dose prescribed to the point A combining EBRT with ICBT was not more than 75-85Gy. To avoid the negative impact of treatment prolongation, it was recommended that the overall treatment time ranged between 7 to 8 weeks. Dose to surrounding organs at risk were calculated at bladder, rectal and pelvic wall points (point B) (Fig. 2). Baseline evaluation and follow-up: Tumor size was assessed clinically by examiner prior to, and following treatment. Initial work-up included a complete blood and platelet counts (CBC), creatinine (Cr), liver function tests (SGPT, Alk.P., Gamma GT). Abdominopelvic CT or MRI, and chest X-ray (CXR). During treatment, patients had weekly CBC, Cr, and liver function tests. Patients who developed any allergic reac-
3 Rasha M. Abdel-Latif, et al. 353 tions during cisplatin and paclitaxel, were subsequently pretreated with dexamethasone 8mg orally every 8 hours for three doses prior to the admission for chemotherapy. After completing therapy, Patients were followed-up by physical examination, and Papanicolaou smear every 3 months for 2 years, and every 6 months for thereafter. Chest X-ray, abdominopelvic CTor MRI was performed every 6 months. Recurrence of disease was defined as the presence of tumor histologically or radiologically. Any suspicious lesion on CT scan was followedup with CT scans every 3 months until the recurrence was confirmed clinically. for progression at the end of radiation therapy, which is approximately 2 and half months from the date of entry. Disease free survival was defined as alive with no evidence of disease at the time of last follow-up or dead without evidence of disease. Survival was calculated from the date of entry to the date of death or last follow-up. Treatment related toxicity was assessed as a secondary endpoint. Adverse events were graded according to the National Cancer Institute Common Toxicity Criteria grading system. The incidence, severity, and causal relation to treatment of these events were compared between treatment groups. Statistical methods: Cumulative survival rates was estimated by the Kaplan-Meier method and compared using the Logrank tests. Chi-square and the student t- test were used for comparative analyses. Statistical significance was defined as p<0.05. Data were analyzed using a SPSS program version Results Fig. (1): Applicator for brachytherapy. Point A Point B Fig. (2): Calculated dose at points A and B. Compliance to treatment: Hematologic, gastrointestinal, renal, and neurotoxicities were evaluated after each cycle of chemotherapy according to the NCI Common Terminology Criteria for Adverse Events, version 3.0. Study end points: The primary endpoints were treatment response, overall survival, and time to relapse. Time to relapse was defined from the the date of first assess with complete response to the date of recurrence. Patients with progressive disease who never achieved complete response, were censored Patient s characteristics: From October 2010 to July 2013, 57 patients were recruited and randomly assigned into two treatment arms, either arm I with 29 patients or arm II with 28 patients. In arm I, 3 were excluded from all analyses: 2 because of incorrect initial staging, 1 who could not subsequently be contacted and in arm II, 3 patients who refused the treatment regimen after randomization. A total of 51 patients received complete treatment as defined per protocol or with an acceptable variation. The baseline characteristics of the study patients are shown in Table (1). Age, histology, stage distribution and lymph node involvement were not different in both groups. Only median tumor size was slightly larger for group II patients (5.5cm) compared to that of group I patients (4cm), but this was not statistically significant (p=0. 16). Compliance to treatment: The two based chemoradiation regimens were tolerated very well, with 88.4% and 84% of patients receiving 4 doses of scheduled chemotherapy cycles for the weekly cisplatin and paclitaxel arms, respectively. There was no statistically significant difference of compliance between the two arms (p>0.05). There were only 5 patients with radiation delay due to toxicity (2 cases in the cisplatin arm and 3 cases in the paclitaxel arm) (Table 2).
4 354 Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy Table (1): Clinical characteristics of patients with locally advanced cervical cancer. Table (3): Incidence and types of acute toxicity in patients with locally advanced cervical cancer. Character Group I Group II No. % No. % Number of patients Median age (years) Performance status: Stage: Stage IIB Stage III Stage VIA Histology: SCC Non-SCC Median tumor size (cm) 4 (2.6-7) 5.5 (4-10) Pretreatment imaging: Positive pelvic LN Positive para-aortic LN Enrolled as pelvic recurrence Table (2): Compliance to treatment in patients with locally advanced cervical cancer Treatment Group I Group II No. % No. % Chemotherapy cycles: >4 cycles Radiotherapy Completed as scheduled Delayed 1-2wk Toxicity of treatment: Treatment related acute toxicity is listed in Table (3). Both groups had comparable hematological toxicity, but more patients in group II had severe diarrhea (44% vs. 26.9%), and allergic reactions (20% vs. 7%). In group II, 4 patients, chemotherapy had to be discontinued because of drug-related allergic reactions. Also, delay in chemotherapy was more common with group II than with group I patients (33% vs. 20%), but this difference was not statistically significant ( p>0.05). Toxicity Progression free survival Group Cisplantin Taxol Cisplantin-censor Taxol-censored Group I Group II No. % No. % Hematologic: Neutropenia Anaemia Thrombocytopenia Non hematologic: Nausea & vomiting (Grade 1-2) C ti i (G d 1 2) Neuropathy-sensory (Grade 1-2) Diarrhea (Grade 3-4) Allergic reactions Alopecia (Grade 1-2) Survival: At two years, local control rates were 90% for group I and 83% for group II ( p=ns). Most of the recurrences occurred in distant sites (4 patients, 15%) in the arm 1 and (5 patients, 20%) in the arm 2, including the para-aortic lymph node and lung parenchyma. Progression free survival at 2-years was 45% at arm I and 38% with arm II, with no statistically significant difference ( p=0.8). Results of Kaplan-Meier estimates of relapse free survival in both treatment arms are shown in Fig. (3). Survival Functions Time in months Fig. (3): Kaplan-Meier analysis of progression free survival per treatment group. Response: Response assessment was done 4-6 weeks after the completion of treatment by doing Abdominopelvic CT or MRI. Overall response rate was 73% in arm I (12 patients achieved complete response (CR) and 7 patients achieved (PR) while OAR was 68% in arm II (10 CR, 7 PR), with no statistically significant difference between the two groups (p>0.05). At a median follow-up of 20 months of all analyzed patients, the median overall survival in arm I was 27 months (95% CI: to ), ranging from months vs 26 (95% CI: to ) months, ranging from months in arm II, with no statistically significant difference (p=0. 16) The 2-year overall survival in arm I was 80% vs 75% in arm II, with no statistically significant difference (p=0.43), (Fig. 4).
5 Rasha M. Abdel-Latif, et al. 355 Overall survival Group Cisplantin Taxol Cisplantin-censor Taxol-censored Survival Functions Time in months Fig. (4): Kaplan-Meier analysis of Overall survival per treatment group. Discussion Cervical cancer is one of the leading causes of cancer incidence and mortality in woman all over the world. Concurrent chemo-radiotherapy was the standard treatment approach for locally advanced cases using platinum based chemotherapy [17]. Although it is widely accepted that cisplatin-based chemoradiation is the standard treatment for locally advanced cervical carcinoma, many drugs were tried in this setting to improve on what can be achieved by concurrent cisplatin [18,19]. The aim of this study is to elicit other chemotherapeutic agent (paclitaxel) concurrent with radiotherapy in comparison with the standard regimen (cisplatin). The result of this small phase II study showed comparable outcome as regard two year overall survival 80% in cisplatin group vs 75% in paclitaxel group and progression free survival 45% in cisplatin and 38% in paclitaxel in addition to similar response rate 73% in group I and 68% in group II with no superiority of paclitaxel over cisplatin as weekly regime, In spite of a little survival benefit in cisplatin group but this statistically insignificant that may be became more evident at prolonged followup or due to median tumor size was slightly larger for group II patients (5.5cm) compared to that of group I patients (4cm). Our result is comparable to data came from Fady et al., [16] at two year survival analysis that showed more or less the same survival 78% for cisplatin and 73% for paclitaxel group. The same result was found in Lanciano et al., larger study by the GOG which also compared concurrent either weekly cisplatin or protracted 5- fluorouracil (5-Fu) infusion. The results of that study showed no superiority of the experimental 5-Fu arm and the study was prematurely closed [20]. The idea of including chemotherapy concurrent with radiotherapy was started after 1999 where randomized studies including nearly 2,000 patients were published, demonstrating that survival rate with concomitant chemotherapy (RT/CT) based on cisplatin was superior than that obtained with radiation alone [4,21,22]. Afterwards, a meta-analysis based on 19 trials (17 published and two unpublished) including 4,580 patients corroborated these findings, confirming that chemoradiation offers an absolute survival benefit of 12% at 5 years [23]. An update of the aforementioned meta-analysis strongly suggests that chemoradiation improves overall survival and progression-free survival, whether or not platinum was used, with absolute benefits of 10 and 13%, respectively [24]. In all previous studies of cervical cancer paclitaxel were used in conjunction with either cisplatin) or carboplatin but was never used alone for CTRT. Most of these studies were phase I [25]. The number of patients enrolled in these studies varied between 8 and 35 patients and the rates of progression free survival ranged between 39 and 88%. The dose limiting toxicity was primarily hematological and small intestinal toxicities [14,26,27]. In this study the toxicity profile was comparable in both groups as regard hematological toxicity with more GIT toxicity in group II, diarrhea (44% vs. 26.9%), and more allergic reaction also, in group II (20% vs. 7%). Also, a delay in chemotherapy was more common with group II than with group I patients (33% vs. 20%), but this difference was not statistically significant (p>0.05). The toxicity profile seen in this study tends to be more in paclitaxel group which was the reverse reported by Vijayakumar et al., [28], that may be attributed to different radiotherapy technique used in Vijayakumar trial which used anterior and posterior portals in cisplatin group while used four fields in paclitaxel group, but in our trial we used four fields technique in both groups. On other hands, our toxicity profile was comparable to data reported by Fady et al., The rate of gastrointestinal (GI) toxicity as severe diarrhea, was high in both arms although slightly higher in the paclitaxel arm, and in general, more chemotherapy delays were encountered in this group. This result was also reported in the preliminary
6 356 Concurrent Weekly Taxol Versus Weekly Cisplatin with Radiotherapy pilot phase I study by Hennequin et al., 26% had grade 3 small bowel toxicity and in addition to grade 3 bladder toxicity and grade 4 mucositis [29]. DiSilvestro et al., [30], reported similar result in his phase I/II trial evaluating toxicity profile of paclitaxel and cisplatin weekly regimen, two had grade 3 or 4 gastrointestinal (GI) toxicities and seven experienced grade 3 or 4 neutrophil toxicity. Conclusion: All the previous data were supporting the use of concurrent cisplatin with radiotherapy in treatemt of locally advanced cervical cancer. On other hand the data supporting the use of paclitaxel in this setting was weak. The conclusion of our study demonstrates non superiority of paclitaxel over cisplatin in concurrent setting an addition to more GIT toxicity and more allergic reaction. These data show that concurrent chemoradiation for advanced cervical cancer using weekly paclitaxel was not superior to concurrent cisplatin and was possibly associated with more severe gastrointestinal toxicity and more allergic reactions. In contrast, progression free survival and two year survival were similar failure at distant sites remains high in both groups, which may indicate the need for additional effective therapy. References 1- GARCIA A., BLESSING J., DARCY K., et al.: Phase II clinical trial of capecitabine in the treatment of advanced, persistent or recurrent squamous cell carcinoma of the cervix with translational research: A gynecologic oncology group study. Gynecol. Oncol., 104: , EINHORN N., TROPE C., RIDDERHEIN M., et al.: A systemic overview of radiation therapy effects in cervical cancer (cervix uteri). Acta. Oncol., 42: , KLOPP A. and EIFEL P.: Chemoradiotherapy for cervical cancer in Curr. Oncol., 13: 77-85, ROSE P., BUNDY B., WATKINS E., et al.: Concurrent cisplatin-based radiotherapy and chemotherapy improves progression-free survival in advanced cervical cancer: results of a randomized gynecologic oncology group study. New Engl. J. Med., 340: , EIFEL P., WINTER K., MORRIS M., et al.: Pelvic irradiation with concurrent chemotherapy versus pelvic and para-aortic irradiation for high risk cervical cancer: An update of radiation therapy oncology group trial (RTOG) J. Clin. Oncol., 22: , KIM Y., SHIN S., CHOI E., et al.: A preliminary result of a randomized trial comparing monthly 5-flourouracil and cisplatin to weekly cisplatin alone combined with concurrent radiotherapy for locally advanced cervical cancer. Cancer Res. Tret., 37: 37-43, ROSE P., ALI S., WATKINS E., et al.: Long-term followup of a randomized trial comparing concurrent single agent cisplatin, cisplatin-based combination chemotherapy, or hydroxyurea during pelvic irradiation for locally advanced cervical cancer: A gynecologic oncology group study. J. Clin. Oncol., 25: , RYU S., LEE W., KIM K., et al.: Randomised clinical trial of weekly vs. triweekly cisplatin-based chemotherapy concurrent with radiotherapy in the treatment of locally advanced cervical cancer. Int. J. Radiat. Oncol. Biol. Phys., 81: e , YAN H., ZHI-QIANG C. and XIAO-YAN S.: Concurrent weekly cisplatin versus triweekly cisplatin versus triweekly cisplatin with radiotherapy in the treatment of cervical cancer: ameta-analysis result. Asian Pacific J. Cancer Prevention, 13: , PEAREEY R., BRUNDAGE M., DROULIN P., et al.: Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J. Clin. Oncol., 20: , MOORE D., BLESSING J., MCQUELLON R., et al.: Phase III study of cisplatin with or without paclitaxel in stage IVB, recurrent, or persistent squamous cell carcinoma of the cervix: A gynecologic oncology group study. J. Clin. Oncol., 22: , PRADIER O., RAVE-FRANK M., SCHMIDBERGER H., et al.: Effects of paclitaxil in combination with radiation on human head and neck cancer cells (ZMK-1), cervical squamous cell carcinoma (CaSki), and breast adenocarcinoma cells (MCF-7). J. Cancer Res. Clin. Oncol., 125: 20-27, BRITTEN R., PERDUE S., OPOKU J., et al.: Taxol is preferentially cytotoxic to human cervical tumor cells with Raf-1 kinase activity: Implication for taxol-based chemoradiation regimens. Radiother Oncol., 48: , CHEN M.D., PALEY P.J., POTISH R.A. and TWIGGS L.B.: Phase I trial of taxol as a radiation sensitizer with cisplatin in advanced cervical cancer. Gynecol. Oncol., 67: , VOGI H., MARTIN T., KOLOTAS C., et al.: Simultaneous taxol and radiotherapy: Initial clinical experience in lung cancer and other malignancies. Semin. Oncol., 24: , FADY B., ALI S., ALI L., et al.: A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer. Radiation Oncology, 5: 84-89, THOMAS G.M.: Improved treatment for cervical cancer concurrent chemotherapy and radiotherapy. N. Engl. J. Med., 340: , PAPADIMITRIOU C., SARRIS K., MOULOPOULOS L., et al.: Phase II trial of taxol and cisplatin in metastatic and recurrent carcinoma of the cervix. J. Clin. Oncol., 17: 761-6, KUDELKA A., WINN R., EDWARDS C., et al.: Activity of taxol in advanced or recurrent squamous cell cancer of the cervix. Clin. Cancer Res., 2: , LANCIANO R., CALKINS A., BUNDY B., et al.: Randomized comparison of weekly cisplatin or protracted
7 Rasha M. Abdel-Latif, et al. 357 venous infusion of fluorouracil in combination with pelvic radiation in advanced cervix cancer: A gynecologic oncology group study. J. Clin. Oncol., 23: , PETERS W., LIU P., BARRETT R., et al.: Concurrent chemotherapy and pelvic radiation therapy compared with pelvic radiation therapy alone as adjuvant therapy after radical surgery in high-risk early-stage cancer of the cervix. J. Clin. Oncol., 18: , WHITNEY C., SAUSE W., BUNDY B., et al.: A randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stages IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes. A gynecologic oncology group and southwest oncology group study. J. Clin. Oncol., 17: , GREEN J., KIRWAN J. and TIERNEY J.: Survival and recurrence after concomitant chemotherapy and radiotherapy for cancer of the uterine cervix: A systematic review and meta-analysis. Lancet, 358: , GREEN J., KIRWAN J., TIERNEY J., et al.: Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst. Rev., CD002225, DISILVESTRO P., WALKER J., MORRISON A., et al.: Gynecologic oncology group. Radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the gynecologic oncology group. Gynecol. Oncol., 103: , CERROTTA A., GARDAN G., CAVINA R., et al.: Concurrent radiotherapy and weekly paclitaxel for locally advanced or recurrent squamous cell carcinoma of the uterine cervix. A pilot study with intensification of dose. Eur. J. Gynaecol. Oncol., 23: , PIGNATA S., FREZZA P., TRAMONTANA S., et al.: Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with carcinoma of the cervix uteri. Ann. Oncol., 11: , VIJAYAKUMAR N., BIBEK B. and SAMIR S.: External beam therapy in a four-field box technique with paclitaxel versus a two-field technique with cisplatin in locally advanced carcinoma cervix: A phase II monocentric trial. International scholarly research network ISRN Oncology Volume, Article ID , 6 Pages, HENNEQUIN C., GIOCANTI N. and FAVAUDON V.: Interaction of ionizing radiation with paclitaxel (Taxol) and docetaxel (Taxotere) in HeLa and SQ20B cells. Cancer Res., 56: , DISILVESTRO P.A., WALKER J.L., MORRISON A., et al.: Gynecologic oncology group. radiation therapy with concomitant paclitaxel and cisplatin chemotherapy in cervical carcinoma limited to the pelvis: A phase I/II study of the gynecologic oncology group. Gynecol. Oncol., 03: , 2006.
Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer
REVIEW ARTICLE Weekly Versus Triweekly Cisplatin-Based Chemotherapy Concurrent With Radiotherapy in the Treatment of Cervical Cancer A Meta-Analysis Xingxing Chen, MD,* Haizhou Zou, MD,Þ Huifang Li, MD,*
More informationEui-Sok Sol 1, Tae Sung Lee 1, Suk Bong Koh 1, Hun Kyu Oh 2, Gi Won Ye 3, Youn Seok Choi 1 INTRODUCTION
J Gynecol Oncol Vol. 20, No. 1:28-34, March 2009 DOI:10.3802/jgo.2009.20.1.28 Original Article Comparison of concurrent chemoradiotherapy with cisplatin plus 5-fluorouracil versus cisplatin plus paclitaxel
More informationChapter 5 Stage III and IVa disease
Page 55 Chapter 5 Stage III and IVa disease Overview Concurrent chemoradiotherapy (CCRT) is recommended for stage III and IVa disease. Recommended regimen for the chemotherapy portion generally include
More informationJ Clin Oncol 22: by American Society of Clinical Oncology INTRODUCTION
VOLUME 22 NUMBER 5 MARCH 1 2004 JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T Pelvic Irradiation With Concurrent Chemotherapy Versus Pelvic and Para-Aortic Irradiation for High-Risk Cervical
More informationINTRODUCTION. J. Radiat. Res., 53, (2012)
J. Radiat. Res., 53, 281 287 (2012) The Effects of Two HDR Brachytherapy Schedules in Locally Advanced Cervical Cancer Treated with Concurrent Chemoradiation: A Study from Chiang Mai, Thailand Ekkasit
More informationLocally advanced disease & challenges in management
Gynecologic Cancer InterGroup Cervix Cancer Research Network Cervix Cancer Education Symposium, February 2018 Locally advanced disease & challenges in management Carien Creutzberg Radiation Oncology, Leiden
More informationPragyat Thakur 1,2, Rajeev Seam 1, Manoj Gupta 1, Manish Gupta 1. Introduction
Original Article on Newer Agents to Enhance Radiotherapeutic Outcomes Page 1 of 8 Prospective randomized study comparing concomitant chemoradiotherapy using weekly cisplatin & paclitaxel versus weekly
More informationComparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail
Comparative Efficacy of Cisplatin vs. Gemcitabine as Concurrent Chemotherapy for Untreated Locally Advanced Cervical Cancer: A Randomized Trail Dr. Nishee Srivastava MD, Dr. Kamal Sahani MD, Dr. Manoj
More informationreceive adjuvant chemotherapy
Women with high h risk early stage endometrial cancer should receive adjuvant chemotherapy Michael Friedlander The Prince of Wales Cancer Centre and Royal Hospital for Women The Prince of Wales Cancer
More informationCOX-2 inhibitor and irradiation. Saitama Cancer Center Kunihiko Kobayashi MD, PhD
COX-2 inhibitor and irradiation Saitama Cancer Center Kunihiko Kobayashi MD, PhD Synthesis of prostaglandins from arachidonic acid by cyclooxygenase (COX) enzymes JNCI 95:1440, 2003 Difference between
More informationUpdate on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer
Update on Neoadjuvant Chemotherapy (NACT) in Cervical Cancer Nicoletta Colombo, MD University of Milan-Bicocca European Institute of Oncology Milan, Italy NACT in Cervical Cancer NACT Stage -IB2 -IIA>4cm
More informationPRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX
PRINCESS MARGARET CANCER CENTRE CLINICAL PRACTICE GUIDELINES GYNECOLOGIC CANCER CERVIX Site Group: Gynecology Cervix Author: Dr. Stephane Laframboise 1. INTRODUCTION 3 2. PREVENTION 3 3. SCREENING AND
More informationHigh-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible??
DOI 10.1007/s13224-015-0812-8 ORIGINAL ARTICLE High-Dose-Rate Orthogonal Intracavitary Brachytherapy with 9 Gy/Fraction in Locally Advanced Cervical Cancer: Is it Feasible?? Saptarshi Ghosh 1 Pamidimukalabramhananda
More informationGynecologic Cancer InterGroup Cervix Cancer Research Network. Management of Cervical Cancer in Resource Limited Settings.
Management of Cervical Cancer in Resource Limited Settings Linus Chuang MD Conflict of Interests None Cervical cancer is the fourth most common malignancy in women worldwide 530,000 new cases per year
More informationRESEARCH ARTICLE. Kuanoon Boupaijit, Prapaporn Suprasert* Abstract. Introduction. Materials and Methods
RESEARCH ARTICLE Survival Outcomes of Advanced and Recurrent Cervical Cancer Patients Treated with Chemotherapy: Experience of Northern Tertiary Care Hospital in Thailand Kuanoon Boupaijit, Prapaporn Suprasert*
More informationLong Term Outcome after Concurrent Chemo radiation with Cisplatin in Carcinoma Cervix
www.jmscr.igmpublication.org Impact Factor 5.84 Index Copernicus Value: 71.58 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v5i10.03 Long Term Outcome after Concurrent Chemo
More informationchemoradiation. Each of these trials had slightly different interventions,
Research ONCOLOGY Radiation therapy with or without weekly cisplatin for bulky stage 1B cervical carcinoma: follow-up of a Gynecologic Oncology Group trial Frederick B. Stehman, MD; Shamshad Ali, MS, MStat;
More informationConcurrent chemoradiotherapy with low-dose daily cisplatin for high risk uterine cervical cancer: a long-term follow-up study
Original Article J Gynecol Oncol Vol. 24, No. 2:108-113 http://dx.doi.org/10.3802/jgo.2013.24.2.108 pissn 2005-0380 eissn 2005-0399 Concurrent chemoradiotherapy with low-dose daily cisplatin for high risk
More informationUPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER
UPDATE IN THE MANAGEMENT OF INVASIVE CERVICAL CANCER Susan Davidson, MD Professor Department of Obstetrics and Gynecology Division of Gynecologic Oncology University of Colorado- Denver Anatomy Review
More informationGCIG Rare Tumour Brainstorming Day
GCIG Rare Tumour Brainstorming Day Relatively (Not So) Rare Tumours Adenocarcinoma of Cervix Keiichi Fujiwara, Ros Glasspool Benedicte Votan, Jim Paul Aim of the Day To develop at least one clinical trial
More informationQuimio Radioterapia en Cancer de Cervix
Quimio Radioterapia en Cancer de Cervix HIGINIA R. CÁRDENES PROFESSOR RADIATION ONCOLOGY CLINICAL DIRECTOR SCHNECK CANCER CENTER Worldwide incidence of cervical cancer 2014, 12.360 cases Global incidence
More informationCase Scenario 1. History
History Case Scenario 1 A 53 year old white female presented to her primary care physician with post-menopausal vaginal bleeding. The patient is not a smoker and does not use alcohol. She has no family
More informationOriginal article. Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy. to patients with carcinoma of the cervix uteri.
Annals of Oncology : 455^59, 2O00. 2000 Kluwer Academic Publishers. Printed in the Netherlands. Original article Phase I study with weekly cisplatin-paclitaxel and concurrent radiotherapy in patients with
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Carcinoma of the Uterine Cervix
THIS DOCUMENT North of Scotland Cancer Network Carcinoma of the Uterine Cervix UNCONTROLLED WHEN PRINTED DOCUMENT CONTROL Prepared by A Kennedy/AG Macdonald/Others Approved by NOT APPROVED Issue date April
More informationThe New England Journal of Medicine
The New England Journal of Medicine Copyright, 1999, by the Massachusetts Medical Society VOLUME 340 A PRIL 15, 1999 NUMBER 15 PELVIC RADIATION WITH CONCURRENT CHEMOTHERAPY COMPARED WITH PELVIC AND PARA-AORTIC
More informationConcurrent chemoradiation in treatment of carcinoma cervix
N. J. Obstet. Gynaecol Vol. 2, No. 1, p. 4-8 May -June 2007 REVIEW Concurrent chemoradiation in treatment of carcinoma cervix Meeta Singh, Rajshree Jha, Josie Baral, Suniti Rawal Dept of Obs/Gyn, TU Teaching
More informationNordic Society for Gynecological Oncology Advisory Board of Radiotherapy
Nordic Society for Gynecological Oncology Advisory Board of Radiotherapy Guidelines for postoperative irradiation of cervical cancer Contents: 1. Treatment planning for EBRT. 2 2. Target definition for
More informationINTRODUCTION PATIENT. J. Radiat. Res., 52, (2011)
J. Radiat. Res., 52, 54 58 (2011) Regular Paper Intracavitary Combined with CT-guided Interstitial Brachytherapy for Locally Advanced Uterine Cervical Cancer: Introduction of the Technique and a Case Presentation
More informationStudy Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus
Study Title The SACS trial - Phase II Study of Adjuvant Therapy in CarcinoSarcoma of the Uterus Investigators Dr Bronwyn King, Peter MacCallum Cancer Centre Dr Linda Mileshkin, Peter MacCallum Cancer Centre
More informationAdjuvant Therapies in Endometrial Cancer. Emma Hudson
Adjuvant Therapies in Endometrial Cancer Emma Hudson Endometrial Cancer Most common gynaecological cancer Incidence increasing in Western world 1-2% cancer deaths 75% patients postmenopausal 97% epithelial
More informationProspective comparative study of dose dense neo-adjuvant chemotherapy followed by chemo-radiation and definitive chemoradiation
International Journal of Reproduction, Contraception, Obstetrics and Gynecology Karpurmath SV et al. Int J Reprod Contracept Obstet Gynecol. 2016 Sept;5(9):2909-2914 www.ijrcog.org pissn 2320-1770 eissn
More informationORIGINAL ARTICLE. Summary. Introduction
Journal of BUON 17: 740-745, 2012 2012 Zerbinis Medical Publications. Printed in Greece ORIGINAL ARTICLE Cisplatin monotherapy with concurrent radiotherapy versus combination of cisplatin and 5-fluorouracil
More informationhttps://patient.varian.com/sit es/default/files/videos/origin al/imrt.mp4 brachy- from Greek brakhys "short" Historically LDR has been used. Cs-137 at 0.4-0.8 Gy/h With optimally placed device, dose
More informationOutcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_
bs_bs_banner doi:10.1111/j.1447-0756.2012.01871.x J. Obstet. Gynaecol. Res. Vol. 38, No. 11: 1315 1320, November 2012 Outcomes and prognostic factors of cervical cancer after concurrent chemoradiationjog_1871
More informationA PILOT STUDY OF FIRST-LINE CHEMOTHERAPY WITH 5-FU AND PLATINUM IN ADVANCED AND RECURRENT CANCER OF THE CERVIX
A PILOT STUDY OF FIRST-LINE CHEMOTHERAPY WITH 5-FU AND PLATINUM IN ADVANCED AND RECURRENT CANCER OF THE CERVIX F. Ghaemmaghami 1, N. Behtash 1, F. Yarandi 1, A. Moosavi 1, Gh.R. Toogeh 2 and N. Khanafshar
More informationThe Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy
The Effect of Treatment Time in Locally Advanced Cervical Cancer in the Era of Concurrent Chemoradiotherapy Suisui Song, MD 1 ; Sonali Rudra, MD 1 ; Michael D. Hasselle, MD 2 ; Paige L. Dorn, MD 1 ; Loren
More informationPrognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic lymph node metastases
Original Article J Gynecol Oncol Vol. 24, No. 3:229-235 pissn 2005-0380 eissn 2005-0399 Prognostic factors and treatment outcome after radiotherapy in cervical cancer patients with isolated para-aortic
More informationRadiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK
Lead Group Log Radiotherapy & Cervical Cancer Dr Mary McCormack Consultant Clinical Oncologist University College Hospital, London,UK Cervical Cancer treatment Treatment planning should be made on a multidisciplinary
More informationHypofractionated RT in Cervix Cancer. Anuja Jhingran, MD
Hypofractionated RT in Cervix Cancer Anuja Jhingran, MD Hypofractionated RT in Cervix Cancer: Clinicaltrials.gov 919 cervix trials 134 hypofractionated RT trials Prostate, breast, NSCLC, GBM 0 cervix trials
More informationPORTEC-4. Patient seqnr. Age at inclusion (years) Hospital:
May 2016 Randomisation Checklist Form 1, page 1 of 2 Patient seqnr. Age at inclusion (years) Hospital: Eligible patients should be registered and randomised via the Internet at : https://prod.tenalea.net/fs4/dm/delogin.aspx?refererpath=dehome.aspx
More informationChapter 8 Adenocarcinoma
Page 80 Chapter 8 Adenocarcinoma Overview In Japan, the proportion of squamous cell carcinoma among all cervical cancers has been declining every year. In a recent survey, non-squamous cell carcinoma accounted
More informationEditorial Process: Submission:09/12/2017 Acceptance:06/19/2018
DOI:10.22034/APJCP.2018.19.10.2745 Concurrent Chemo-Radiobrachytherapy in Cervical Cancer RESEARCH ARTICLE Editorial Process: Submission:09/12/2017 Acceptance:06/19/2018 Concurrent Chemo- Radiobrachytherapy
More informationARROCase: Locally Advanced Endometrial Cancer
ARROCase: Locally Advanced Endometrial Cancer Charles Vu, MD (PGY-3) Faculty Advisor: Peter Y. Chen, MD, FACR Beaumont Health (Royal Oak, MI) November 2016 Case 62yo female with a 3yr history of vaginal
More informationNorth of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer
THIS DOCUMENT North of Scotland Cancer Network Clinical Management Guideline for Endometrial Cancer Based on WOSCAN CMG with further extensive consultation within NOSCAN UNCONTROLLED WHEN PRINTED DOCUMENT
More informationRole of Twice Weekly HDR- Brachytherapy in Management of Carcinoma Of Uterine Cervix-Experience of Rural Centre in India
Global Journal of Medical research Interdsciplinary Volume 13 Issue 4 Version 1.0 Year 2013 Type: Double Blind Peer Reviewed International Research Journal Publisher: Global Journals Inc. (USA) Online
More informationPILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia)
PILOT STUDY OF CONCURRENT CHEMO-RADIOTHERAPY FOR ADVANCED NASOPHARYNGEAL CARCINOMA (Forum for Nuclear Cooperation in Asia) Dr. Miriam Joy C. Calaguas Dept. of Radiation Oncology St. Luke s Medical Center
More informationPatterns of Care in Patients with Cervical Cancer:
Patterns of Care in Patients with Cervical Cancer: Power and Pitfalls of Claims-Based Analysis Grace Smith, MD, PhD, MPH Resident, PGY-5 Department of Radiation Oncology, MD Anderson Cancer Center Acknowledgments
More informationONCOLOGY LETTERS 3: , 2012
ONCOLOGY LETTERS 3: 641-645, 2012 Treatment of early bulky cervical cancer with neoadjuvant paclitaxel, carboplatin and cisplatin prior to laparoscopical radical hysterectomy and pelvic lymphadenectomy
More informationIsolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix
J Nepal Health Res Counc 2009 Oct;7(15):103-7 Original Article Isolated Para-Aortic Lymph Nodes Recurrence in Carcinoma Cervix Ghimire S 1, Hamid S, 2 Rashid A 2 1 Bhaktapur Cancer Hospital, Bhaktapur,
More informationtrial update clinical
trial update clinical by John W. Mucenski, BS, PharmD, Director of Pharmacy Operations, UPMC Cancer Centers The treatment outcome for patients with relapsed or refractory cervical carcinoma remains dismal.
More informationChemotherapy for Cervical Cancer. Matsue City Hospital Junzo Kigawa
Chemotherapy for Cervical Cancer Matsue City Hospital Junzo Kigawa Introduction Worldwide, cervical cancer is the second most common cancer in women and affects 530,000 new patients and 275,000 deaths.
More informationBCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy
BCCA Protocol Summary for Combined Modality Adjuvant Therapy for High Risk Rectal Carcinoma using Capecitabine and Radiation Therapy Protocol Code: Tumour Group: Contact Physician: GIRCRT Gastrointestinal
More informationDocetaxel. Class: Antineoplastic agent, Antimicrotubular, Taxane derivative.
Docetaxel Class: Antineoplastic agent, Antimicrotubular, Taxane derivative. Indications: -Breast cancer: -Non small cell lung cancer -Prostate cancer -Gastric adenocarcinoma _Head and neck cancer Unlabeled
More informationOriginal Article INTRODUCTION. Abstract
Original Article Print ISSN: 2321-6379 Online ISSN: 2321-595X DOI: 10.17354/ijss/2018/251 A Prospective Analysis of Toxicities and Quality of Life after Treatment in Advanced Carcinoma Cervix Patients
More informationA phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008
A phase II study of weekly paclitaxel and cisplatin followed by radical hysterectomy in stages IB2 and IIA2 cervical cancer AGOG14-001/TGOG1008 NCT02432365 Chyong-Huey Lai, MD On behalf of Principal investigator
More informationCervical CA: What is Advanced Stage? If the tumor is early stage but >4cm (IB2 or IIA2), it is often treated as advanced stage (category 1) but also h
PROGRAMA 2 Taller Internacional Multidisciplinario de Cancer de Mama y Cuello Uterino Racional del tratamiento combinado con Quimioterapia e Irradiación. Resultados en Cáncer de Cérvix avanzado Higinia
More informationICRT รศ.พญ.เยาวล กษณ ชาญศ ลป
ICRT รศ.พญ.เยาวล กษณ ชาญศ ลป Brachytherapy การร กษาด วยร งส ระยะใกล Insertion การสอดใส แร Implantation การฝ งแร Surface application การวางแร physical benefit of brachytherapy - very high dose of radiation
More informationEfficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer
original studies Efficacy and Toxicity of Neoadjuvant Chemotherapy Followed by Radiochemotherapy in Locally Advanced Cervical Cancer Nemes Adina 1, Nagy Viorica 1, 2, Todor Nicolae 1, Marita Andreea 1,
More informationThe effect of treatment prolongation in treatment of cervical cancer patient treated patients at rural center in India
IOSR Journal of Dental and Medical Sciences (IOSR-JDMS) e-issn: 2279-0853, p-issn: 2279-0861.Volume 9, Issue 2 (Jul.- Aug. 2013), PP 70-75 The effect of treatment prolongation in treatment of cervical
More informationRadiation Oncology MOC Study Guide
Radiation Oncology MOC Study Guide The following study guide is intended to give a general overview of the type of material that will be covered on the Radiation Oncology Maintenance of Certification (MOC)
More informationOriginal Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September Implementation Date: December 2014 Clinical Operations
National Imaging Associates, Inc. Clinical guideline CERVICAL CANCER Original Date: June 2013 Page 1 of 7 Radiation Oncology Last Review Date: September 2014 Guideline Number: NIA_CG_223 Last Revised Date:
More informationMedicinae Doctoris. One university. Many futures.
Medicinae Doctoris The Before and The After: Can chemotherapy revise the trajectory of gastric and esophageal cancers? Dr. David Dawe MD, FRCPC Medical Oncologist Assistant Professor Disclosures None All
More informationAlgorithms for management of Cervical cancer
Algithms f management of Cervical cancer Algithms f management of cervical cancer are based on existing protocols and guidelines within the ESGO comunity and prepared by ESGO Educational Committe as a
More informationCountry Presentations of FNCA FY2007 Workshop on Radiation Oncology
Country Presentations of FNCA FY2007 Workshop on Radiation Oncology Annex 3 Country presentations on CERVIX-III -China: Total Patients: 18, 8 alive: 1 with metastasis lung, another one metastasis to liver;
More informationUniversity Cooperation Platform
Starting a Brachytherapy Program in Government Controlled Healthcare Systems Razvan Galalae, MD, PhD Associate Professor, Medical Faculty, Christian Albrecht University Kiel, Germany, and Head of Radiotherapy
More informationTable Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies
Table Selected Clinical Trials of Anti-Angiogenesis Therapy in Gynecologic Malignancies Uterus Study N Eligibility Regimen RR (No. of Responses) Median OS Grade 3/4 Toxicities Nimeiri et al[42] Total:
More informationDepartment of Radiotherapy, Pt. BDS PGIMS, Rohtak, Haryana, India
Bharti et al., IJPSR, 2010; Vol. 1 (11): 169-173 ISSN: 0975-8232 IJPSR (2010), Vol. 1, Issue 11 (Research Article) Received on 29 September, 2010; received in revised form 21 October, 2010; accepted 26
More informationComparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer
Comparison of rectal and bladder ICRU point doses to the GEC ESTRO volumetric doses in Cervix cancer Poster No.: RO-0049 Congress: RANZCR FRO 202 Type: Authors: Scientific Exhibit G. Govindarajulu, A.
More informationHYPERTHERMIA in CERVIX and VAGINA CANCER. J. van der Zee
HYPERTHERMIA in CERVIX and VAGINA CANCER J. van der Zee ESTRO 2006 Deep hyperthermia in Rotterdam HYPERTHERMIA in CERVIX and VAGINA CANCER ESTRO 2006 Hyperthermia and radiotherapy in primary advanced cervix
More information17 th ESO-ESMO Masterclass in clinical Oncology
17 th ESO-ESMO Masterclass in clinical Oncology Cervical and endometrial Cancer Cristiana Sessa IOSI Bellinzona, Switzerland Berlin, March 28 th, 2018 Presenter Disclosures None Cervical Cancer Estimated
More informationGYNECOLOGIC CANCER and RADIATION THERAPY. Jon Anders M.D. Radiation Oncology
GYNECOLOGIC CANCER and RADIATION THERAPY Jon Anders M.D. Radiation Oncology Brachytherapy Comes from the Greek brakhus meaning short Brachytherapy is treatment at short distance Intracavitary vs interstitial
More informationInterstitial Brachytherapy. Low dose rate brachytherapy. Brachytherapy alone cures some cervical cancer. Learning Objectives
Interstitial Learning Objectives To discuss practical aspects of selection and insertion techniques for interstitial brachytherapy and their relation to clinical trials Akila Viswanathan, MD MPH Johns
More informationYukiharu Todo 1, Hidemichi Watari 2. Abstract
Review Article on Cervical Cancer Concurrent chemoradiotherapy for cervical cancer: background including evidence-based data, pitfalls of the data, limitation of treatment in certain groups Yukiharu Todo
More informationAn Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review of the Literature
Archives of Clinical and Medical Case Reports doi: 10.26502/acmcr.9655003 Volume 1, Issue 1 Case Report An Unusual Case of Cervical Cancer with Inguinal Lymph Node Metastasis: A Case Report and Review
More informationManagement of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D.
Management of high risk early cervical cancer - a view of surgeon Dan DY Kim, M.D., Ph.D. Department of Obstetrics and Gynecology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Korea
More information3/8/2014. Case Presentation. Primary Treatment of Anal Cancer. Anatomy. Overview. March 6, 2014
Case Presentation Primary Treatment of Anal Cancer 65 year old female presents with perianal pain, lower GI bleeding, and anemia with Hb of 7. On exam 6 cm mass protruding through the anus with bulky R
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBiomedical Research 2018; 29 (10):
Biomedical Research 2018; 29 (10): 2116-2121 ISSN 0970-938X www.biomedres.info Concurrent chemoradiotherapy with paclitaxel and cisplatin for patients of locally advanced cervical squamous cell carcinoma:
More informationEvaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy With Cobalt 60 In Carcinoma of Cervix
Iran J Cancer Preven. 2015 August; 8(4):e3573. Published online 2015 August 24. DOI: 10.17795/ijcp-3573 Research Article Evaluation of Survival and Treatment Toxicity With High-Dose-Rate Brachytherapy
More informationChun-Chieh Wang, MD and Feng-Yuan Liu, MD/ Prof. Chyong-Huey Lai, MD
Concept/trial design presentation A Phase 2 Trial of Pembrolizumab Combined with Chemoradiation for Patients with [ 18 F]-FDG PET/CT-defined Poor-prognostic Cervical Cancer Chun-Chieh Wang, MD and Feng-Yuan
More informationCISPLATIN Chemo-radiation regimen Gynaecological Cancer
Systemic Anti Cancer Treatment Protocol CISPLATIN Chemo-radiation regimen Gynaecological Cancer PROCTOCOL REF: MPHAGYNCIX (Version No: 1.0) Approved for use in: Locally advanced cervical cancer (adjuvant/curative)
More informationCase Conference. Craig Morgenthal Department of Surgery Long Island College Hospital
Case Conference Craig Morgenthal Department of Surgery Long Island College Hospital Neoadjuvant versus Adjuvant Radiation Therapy in Rectal Carcinoma Epidemiology American Cancer Society statistics for
More informationWeekly Cisplatin + Radiotherapy - Interlace study -
Weekly Cisplatin + Radiotherapy - Interlace study - A phase III multicentre trial of weekly induction chemotherapy followed by standard chemoradiation versus standard chemoradiation alone in patients with
More informationCURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER
CURRENT STANDARD OF CARE IN NASOPHARYNGEAL CANCER Jean-Pascal Machiels Department of medical oncology Institut I Roi Albert II Cliniques universitaires Saint-Luc Université catholique de Louvain, Brussels,
More informationSponsor / Company: Sanofi Drug substance(s): Docetaxel (Taxotere )
These results are supplied for informational purposes only. Prescribing decisions should be made based on the approved package insert in the country of prescription. Sponsor / Company: Sanofi Drug substance(s):
More informationNasopharyngeal Cancer/Multimodality Treatment
Nasopharyngeal Cancer/Multimodality Treatment PANAGIOTIS KATSAOUNIS Medical Oncologist IASO GENERAL HOSPITAL Athens, 22/10/2016 1 st Hellenic Multidisciplinary Conference on Head and Neck Cancer INTRODUCTION
More informationGCIG Cervix Committee: Chicago, USA May 30th Satoru Sagae (JGOG) Bradley Monk (GOG)
GCIG Cervix Committee: Chicago, USA May 30th 2013 Satoru Sagae (JGOG) Bradley Monk (GOG) Conflict of Interest Disclosures CURRENT ACTIVE/NEAR ACTIVATION RANDOMIZED TRIALS WITH GCIG PARTICIPATION: Wellcome
More informationIs Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally Advanced Cervical Cancer Necessary?
pissn 1598-2998, eissn 2005-9256 Cancer Res Treat. 2014;46(4):374-382 Original Article http://dx.doi.org/10.4143/crt.2013.084 Open Access Is Prophylactic Irradiation to Para-aortic Lymph Nodes in Locally
More informationECC or Margins Positive?
CLINICAL PRESENTATION This practice algorithm has been specifically developed for M. D. Anderson using a multidisciplinary approach and taking into consideration circumstances particular to M. D. Anderson,
More informationCOMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS
COMPARATIVE STUDY ON EFFICACY AND TOXICITY OF CHEMORADIOTHERAPY AND RADIOTHERAPY IN HEAD, NECK AND CERVIX CANCER PATIENTS E.Maheswari 1, G.R.Saraswathy 1, Santh Rani Thaakur 1, Narmada Sambhasivam 2. 1
More informationORIGINAL PAPER. Department of Radiology, Nagoya University Graduate School of Medicine, Aichi, Japan 2
Nagoya J. Med. Sci. 79. 211 ~ 220, 2017 doi:10.18999/nagjms.79.2.211 ORIGINAL PAPER Postoperative chemoradiation therapy using high dose cisplatin and fluorouracil for high- and intermediate-risk uterine
More informationJMSCR Vol 06 Issue 12 Page December 2018
www.jmscr.igmpublication.org Impact Factor (SJIF): 6.379 Index Copernicus Value: 79.54 ISSN (e)-2347-176x ISSN (p) 2455-0450 DOI: https://dx.doi.org/10.18535/jmscr/v6i12.129 Research Paper Establishing
More informationTratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón
Tratamiento Multidisciplinar de Estadios Localmente Avanzados en Cáncer de Pulmón Santiago Ponce Aix Servicio Oncología Médica Hospital Universitario 12 de Octubre Madrid Stage III: heterogenous disease
More informationCervical cancer presentation
Carcinoma of the cervix: Carcinoma of the cervix is the second commonest cancer among women worldwide, with only breast cancer occurring more commonly. Worldwide, cervical cancer accounts for about 500,000
More informationBCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum
BCCA Protocol Summary for Treatment of Advanced Squamous Cell Carcinoma of the Head and Neck Cancer Using Fluorouracil and Platinum Protocol Code: Tumour Group: Contact Physician: HNAVFUP Head and Neck
More informationComparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin in FIGO stage IIB-IVA cervical cancer
Original Article J Gynecol Oncol Vol. 23, No. 4:235-241 pissn 2005-0380 eissn 2005-0399 Comparison of concurrent chemoradiation therapy with weekly cisplatin versus monthly fluorouracil plus cisplatin
More informationENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre)
ENDOMETRIAL CANCER Updated Apr 2017 by: Dr. Jenny Ko (Medical Oncologist, Abbotsford Cancer Centre) Source: UpToDate 2017, ASCO/CCO/Alberta provincial guidelines, NCCN Reviewed by: Dr. Sarah Glaze (Gynecologic
More informationGASTRIC & PANCREATIC CANCER
GASTRIC & PANCREATIC CANCER ASCO HIGHLIGHTS 2005 Fadi Sami Farhat, MD Head of Hematology Oncology Division Hammoud Hospital University Medical Center Saida Lebanon Tel: +961 3 753 155 E-Mail: drfadi@drfadi.org
More informationAOGS MAIN RESEARCH ARTICLE
A C TA Obstetricia et Gynecologica AOGS MAIN RESEARCH ARTICLE Differential clinical characteristics, treatment response and prognosis of locally advanced adenocarcinoma/ adenosquamous carcinoma and squamous
More informationCarboplatin + Paclitaxel Cancer of the Cervix
Carboplatin + Paclitaxel Cancer of the Cervix Background: Topotecan in combination with cisplatin is recommended as a treatment option for women with recurrent or stage IVB cervical cancer only if they
More information